Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Formulation of Liquid Oral Preparations Containing Itraconazole

이트라코나졸의 경구용 액제 처방화

  • Published : 2002.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

The oral bioavailability of itraconazole is variable and low in fasting state. This is mainly due to the low solubility of this drug. Bioavailability can be improved by changing the formulation and it is general that the liquid preparations show greater bioavailability than the solid dosage forms such as tablets and capsules do. Benzyl alcohol-water binary mixture showed the excellent solubilizing capacity for itraconazole but the release of the drug from the preparation needs to be enhanced. In this study, various nonionic surfactants and hydrophilic polymers, poloxamers, were screened to investigate their effects on the releasε of itraconazole from the liquid preparations. Poloxamer 407 showed the most enhancing effect on the drug release and the release rate was proportional to thε amount of poloxamer 407 added. A liquid preparation of itraconazole, consisting of benzyl alcohol/water/poloxamer 407 ternary solvent system, releasεd more than 80% of the total drug amount at 5 min and showεd the possibility of a new formulation development.

Keywords

References

  1. D.W. Warnock, Itraconazole and fluconazole: new drugs for deep fungal infection, J. Antimicro. Chemother., 24, 275-277 (1989) https://doi.org/10.1093/jac/24.3.275
  2. B.L.E. Colette, V. Geert, T. Dany, Antifungal compositions of improved bioavailability, US2001007678 (2001)
  3. M. Skinner, I. Kanfer, Comparative bioavailability of josamycin, a macrolide antibiotic, from a tablet and solution and the influence of dissolution on in vivo release, Biopharm. Drug Dispos., 19, 21-29 (1998) https://doi.org/10.1002/(SICI)1099-081X(199801)19:1<21::AID-BDD69>3.0.CO;2-G
  4. I. Setnikar, K. Schmid, L.C. Rovati, B. Vens-Cappell, D. Mazur, I. Kozak, Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation, Arzneimittelforschung, 51, 2-6 (2001)
  5. J.A. Barone, B.L. Moskovitz, J. Guarnier, A.E. Hassell, J.L. Colaizzi, R.H. Bierman, L. Jessen, Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers, Antimicrob. Agents Chemother., 42, 1862-5 (1998)
  6. Sepcification Report No. A163 (860516) - R51211, Janssen Pharmaceutica
  7. A.H. Kibbe, Handbook of Pharmaceutical Excipients, 3rd Ed., Pharmaceutical Press, London, United Kingdom, 41-43 (2000)
  8. P. Simamora, M. Alvarez, S.H. Yalkowsky, Solubilization of rapamycin, Int. J. Pharm., 213, 25-29 (2001) https://doi.org/10.1016/S0378-5173(00)00617-7
  9. H.-J. Kim, K.A. Yoon, M. Hahn, E.-S. Park, S.-C. Chi, Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone, Drug Dev. Ind. Pharm., 26, 523-529 (2000) https://doi.org/10.1081/DDC-100101263
  10. T. Gershanik, S. Benita, Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs, Eur, J. Pharm. Biopharm., 50, 179-188 (2000) https://doi.org/10.1016/S0939-6411(00)00089-8
  11. A.K. Singla, A. Garg, D. Aggarwal, Paclitaxel and its formulations, Int, J. Pharm., 235, 179-192 (2002) https://doi.org/10.1016/S0378-5173(01)00986-3
  12. M. Trotta, M. Gallaratea, F. Pattarinob, S. Morelb, Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions, J. Control. Rel., 76, 119-128 (2001) https://doi.org/10.1016/S0168-3659(01)00432-1